Division 2.1 Permanent deferral criteria for donors of allogeneic donations
United Kingdom
| Cardiovascular disease | Prospective donors with active or past serious cardiovascular disease, except congenital abnormalities with complete cure |
| Central nervous system disease | A history of serious CNS disease |
| Abnormal bleeding tendency | Prospective donors who give a history of a coagulopathy |
| Repeated episodes of syncope, or a history of convulsions | Other than childhood convulsions or where at least three years have elapsed since the date the donor last took anticonvulsant medication without any recurrence of convulsions |
| Gastrointestinal, genitourinary, haematological, immunological, metabolic, renal, or respiratory system diseases | Prospective donors with serious active, chronic, or relapsing disease |
| Diabetes | If being treated with insulin |
| Infectious diseases | Hepatitis B, except for HBsAg-negative persons who are demonstrated to be immune |
| Hepatitis C | |
| HIV-1/2 | |
| HTLV I/II | |
| Babesiosis (*) | |
| Kala Azar (visceral leishmaniasis) (*) | |
| Trypanosomiasis cruzi (Chagas' disease) (*) | |
| Malignant diseases | Except in situ cancer with complete recovery |
| Transmissible spongiform encephalopathies (TSEs), (e.g. Creutzfeldt Jakob Disease, variant Creutzfeldt Jakob Disease) | Persons who have a family history which places them at risk of developing a TSE, or persons who have received a corneal or dura mater graft, or who have been treated in the past with medicines made from human pituitary glands. For variant Creutzfeldt Jacob disease, further precautionary measures may be recommended. |
| Intravenous (IV) or intramuscular (IM) drug use | Any history of non-prescribed IV or IM drug use, including body-building steroids or hormones |
| Xenotransplant recipients | |
| Sexual behaviour | Persons whose sexual behaviour puts them at high risk of acquiring severe infectious diseases that can be transmitted by blood |